Vorinostat and bortezomib as third-line therapy in patients with advanced non-small cell lung cancer: a Wisconsin Oncology Network Phase II study.

Hoang, Tien; Campbell, Toby C; Zhang, Chong; Kim, Kyungmann; Kolesar, Jill M; Oettel, Kurt R; Blank, Jules H; Robinson, Emily G; Ahuja, Harish G; Kirschling, Ron J; Johnson, Peter H; Huie, Michael S; Wims, Mary E; Larson, Martha M; Hernan, Hilary R; Traynor, Anne M

Hoang, Tien; Campbell, Toby C; Zhang, Chong; Kim, Kyungmann; Kolesar, Jill M; Oettel, Kurt R; Blank, Jules H; Robinson, Emily G; Ahuja, Harish G; Kirschling, Ron J; Johnson, Peter H; Huie, Michael S; Wims, Mary E; Larson, Martha M; Hernan, Hilary R; Traynor, Anne M.

Affiliation

Hoang T; University of Wisconsin Carbone Cancer Center, Madison, WI, USA, txh@medicine.wisc.edu.

Invest New Drugs ; 32(1): 195-9, 2014 Feb.

Article in En | MEDLINE | ID: mdl-23728919

Subject(s)

Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Boronic Acids/therapeutic use; Carcinoma, Non-Small-Cell Lung/drug therapy; Carcinoma, Non-Small-Cell Lung/pathology; Hydroxamic Acids/therapeutic use; Lung Neoplasms/drug therapy; Lung Neoplasms/pathology; Pyrazines/therapeutic use; Aged; Antineoplastic Combined Chemotherapy Protocols/adverse effects; Boronic Acids/adverse effects; Bortezomib; Disease-Free Survival; Female; Humans; Hydroxamic Acids/adverse effects; Male; Middle Aged; Pyrazines/adverse effects; Treatment Outcome; Vorinostat

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: Pyrazines / Boronic Acids / Antineoplastic Combined Chemotherapy Protocols / Carcinoma, Non-Small-Cell Lung / Hydroxamic Acids / Lung Neoplasms Limits: Aged / Female / Humans / Male / Middle aged Language: En Year: 2014 Type: Article

Fulltext

XML

PubMed Links

Search on Google